WASHINGTON, D.C.  20549
                                FORM 12B-25
                        Notification of Late Filing 
                       Commission File Number O-1437
(Check one):   (  ) Form 10-K    (  ) Form 11-K    (  ) Form 20-F 

          (X) Form 10-Q    (  ) Form N-SAR
          For period ended              March 31, 1996
( )  Transition Report on Form 10-K 
( )  Transition Report on Form 20-F 
( )  Transition Report on Form 11-K 
( )  Transition Report on Form 10-Q 
( )  Transition Report on Form N-SAR 

          For the transition period ended
          Nothing in this form shall be construed to imply that
the Commission has verified any information contained herein. 

          If the notification relates to a portion of the filing
checked above, identify the item(s) to which the notification

                                  PART I 
                          REGISTRANT INFORMATION
     Full name of registrant       HALSEY DRUG CO., INC.

     Former name if applicable 

                                  1827 Pacific Street   
Address of principal executive office (Street and Number) 

     City, State and Zip Code      Brooklyn, New York  11233
                                 PART II 
                          RULE 12B-25(B) AND (C)
          If the subject report could not be filed
without unreasonable effort or expense and the registrant seeks
relief pursuant to Rule 12b-25(b), the following should be
completed. (Check where appropriate.) 

( )       (a)  The reasons described in reasonable detail in
Part III ofthis form could not be eliminated without unreasonable
effort or expense; 

(X)       (b)  The subject annual report, semi-annual
report,transition report on Form 10-K, 20-F, 11-K or Form N-SAR,
or portion thereof will be filed on or before the 15th calendar
day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q, or portion, thereof
will be filed on or before the fifth calendar day following the
prescribed due date, and 

( )       (c)  The accountant's statement or other
exhibitrequired by Rule 12b-25(c) has been attached if

                                 PART III 
          State below in reasonable detail the reasons why
Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report
portion thereof could not be filed within the prescribed time
period. (Attach extra sheets if needed.) 

          Financial information from subsidiaries will 
          not be received in sufficient time.
                                  PART IV 
                             OTHER INFORMATION
          (1)  Name and telephone number of person to contact
inregard to this notification. 

     ROSENDO FERRAN                         (718)  467-7500
      (Name)                    (Area Code)  (Telephone Number) 

          (2)  Have all other periodic reports required
under Section 13 or 15(d) or the Securities Exchange Act of 1934
or Section 30 of the Investment Company Act of 1940 during the
preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the
answer is no, identify report(s). 

                                        (X) Yes        ( ) No
          (3)  Is it anticipated that any significant change
in results of operations from the corresponding period for the
last fiscal year will be reflected by the earnings statements to
be included in the subject report or portion thereof? 
                                        ( ) Yes        (X) No
          If so, attach an explanation of the anticipated
change,both narratively and quantitatively, and, if appropriate,
state the reasons why a reasonable estimate of the results cannot
be made. 


                 HALSEY DRUG CO., INC. 
               (Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized. 


Date   May 15, 1996                  By /s/ Rosendo Ferran 
                                 Rosendo Ferran, President and Chief  
                                 Executive Officer